Seres Therapeutics (MCRB) News Today → Invest in the 'Trojan Horse' of Alzheimer's Treatment (From Behind the Markets) (Ad) Free MCRB Stock Alerts $0.92 -0.03 (-3.14%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) PT Lowered to $6.00 at Chardan CapitalMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising PipelineMay 9, 2024 | marketbeat.comOppenheimer Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $4.00Oppenheimer reduced their price objective on shares of Seres Therapeutics from $5.00 to $4.00 and set an "outperform" rating for the company in a research note on Thursday.May 9, 2024 | finance.yahoo.comSeres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comSeres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 8, 2024 | investorplace.comMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024May 8, 2024 | msn.comSeres Therapeutics GAAP EPS of -$0.27 beats by $0.07May 8, 2024 | finance.yahoo.comSeres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue EstimatesMay 8, 2024 | businesswire.comSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | markets.businessinsider.comHere's what to expect from Seres Therapeutics's earningsMay 7, 2024 | marketbeat.comSeres Therapeutics (MCRB) to Release Quarterly Earnings on WednesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 6, 2024 | businesswire.comSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | businesswire.comSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024May 6, 2024 | businesswire.comSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024April 30, 2024 | money.usnews.comSeres Therapeutics IncApril 9, 2024 | businesswire.comSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTMarch 28, 2024 | finance.yahoo.comIncreases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for nowMarch 11, 2024 | finance.yahoo.comMCRB Apr 2024 1.000 putMarch 7, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | realmoney.thestreet.comSeres Therapeutics price target lowered by $4 at Oppenheimer, here's whyMarch 6, 2024 | markets.businessinsider.comSeres Therapeutics (MCRB) Gets a Buy from TD CowenMarch 6, 2024 | finance.yahoo.comQ4 2023 Seres Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023March 5, 2024 | investorplace.comGold Price Alert: Gold Spot Prices Just Hit a Record High TodayMarch 5, 2024 | msn.comSeres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23MMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 5, 2024 | finance.yahoo.comSeres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023March 4, 2024 | benzinga.comSeres Therapeutics's Earnings: A PreviewMarch 2, 2024 | morningstar.comSeres Therapeutics Inc MCRBFebruary 28, 2024 | businesswire.comSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024February 27, 2024 | finance.yahoo.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 27, 2024 | businesswire.comSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceFebruary 26, 2024 | markets.businessinsider.comSeres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David ArkowitzFebruary 26, 2024 | finance.yahoo.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 26, 2024 | businesswire.comSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzFebruary 25, 2024 | marketbeat.comFederated Hermes Inc. Cuts Position in Seres Therapeutics, Inc. (NASDAQ:MCRB)Federated Hermes Inc. cut its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 21.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,981,717 shares of the biotechnology company's stock after selling 2,413,084 shares during theFebruary 22, 2024 | benzinga.comSeres Therapeutics Stock (NASDAQ:MCRB), Short Interest ReportFebruary 18, 2024 | msn.comNew Seres 3 arrives in the UK priced from £29,995February 18, 2024 | msn.comMeet the UK's cheapest new electric SUV: the new Seres 3, yours for just under £30kFebruary 17, 2024 | marketbeat.comEric D. Shaff Sells 11,549 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) StockSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) CEO Eric D. Shaff sold 11,549 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $1.08, for a total value of $12,472.92. Following the transaction, the chief executive officer now directly owns 135,321 shares in the company, valued at $146,146.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.February 14, 2024 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest UpdateSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 15,590,000 shares, a decline of 11.2% from the January 15th total of 17,550,000 shares. Based on an average trading volume of 4,560,000 shares, the short-interest ratio is currently 3.4 days.February 7, 2024 | markets.businessinsider.comSell Rating on Seres Therapeutics Amid Underperforming Sales and Financial ChallengesFebruary 3, 2024 | investing.comSeres Therapeutics Inc (MCRB)January 31, 2024 | msn.comSeres Therapeutics Announces 2024 Virtual Stockholders MeetingJanuary 30, 2024 | msn.comHuawei’s car-making partner Seres expects reduced 2023 losses, with M7 and M9 EVs paving road to profitabilityJanuary 30, 2024 | marketbeat.comShort Interest in Seres Therapeutics, Inc. (NASDAQ:MCRB) Expands By 7.8%Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 17,550,000 shares, an increase of 7.8% from the December 31st total of 16,280,000 shares. Based on an average daily trading volume, of 5,250,000 shares, the days-to-cover ratio is presently 3.3 days.January 16, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Given New $9.00 Price Target at OppenheimerOppenheimer dropped their price objective on shares of Seres Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Tuesday.January 14, 2024 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Drop in Short InterestSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 16,280,000 shares, a decline of 21.8% from the December 15th total of 20,810,000 shares. Based on an average daily trading volume, of 4,870,000 shares, the short-interest ratio is currently 3.3 days.January 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB) Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. MCRB Media Mentions By Week MCRB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼0.350.54▲Average Medical News Sentiment MCRB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼42▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GOSS News Today CAPR News Today PRQR News Today GLSI News Today SCPH News Today SKYE News Today PRLD News Today IVA News Today IXHL News Today CRVO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
